Physician profile
Niraj Sinha
NPI 1275812299
$13,491.99
in general payments reported to CMS, 2019-2025
41 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $1,289 · 2021: $1,296 · 2022: $2,811 · 2023: $1,562 · 2024: $3,145 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,431 · Travel and Lodging: $1,205 · Education: $298 · Consulting Fee: $24.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,431.05 |
| Travel and Lodging | $1,205.44 |
| Education | $297.74 |
| Consulting Fee | $24.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,429.75 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,868.97 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Intuitive Surgical, INC. | $1,347.46 | 2024 | |
| Ethicon INC. | $1,335.17 | 2021-2025 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $904.23 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $726.83 | 2020-2025 | Dupixent |
| Genzyme Corporation | $485.09 | 2019-2025 | |
| Electromed, INC. | $462.05 | 2021-2025 | Smartvest |
| Harmony Biosciences LLC | $348.35 | 2022-2025 | Wakix |
| Grifols USA, LLC | $339.48 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $246.49 | 2019-2025 | Arikayce, Brinsupri |
| Novartis Pharmaceuticals Corporation | $244.12 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $239.63 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Abbvie INC. | $227.01 | 2023-2025 | Avycaz, Teflaro |
| Amgen INC. | $221.49 | 2021-2025 | Tezspire |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.